{
  "pmcid": "11338012",
  "sha256": "9c906597478cf0375e8297d548cee2ec23ad21c86bdce0e97162114189cbd7dd",
  "timestamp_utc": "2025-11-09T22:02:39.155542+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.438151815181524,
    "reading_ease": 18.705830583058315,
    "word_count": 202
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of CNI-Sparing Regimens in Kidney Transplantation"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to either a CNI-sparing regimen or standard CNI-based regimen."
      },
      "Participants": {
        "score": 2,
        "evidence": "This randomised controlled trial included kidney transplant recipients (KTRs) with low-to-moderate immunological risk."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received a CNI-sparing regimen, while the control group received standard CNI-based therapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "To assess the impact of CNI-sparing regimens on long-term allograft function."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was allograft function at 12 months, measured by estimated glomerular filtration rate (eGFR)."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "200 participants were randomised: 100 to the intervention and 100 to the control group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was intention-to-treat."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed improved eGFR (mean difference = 5.2 mL/min/1.73 mÂ², 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the intervention and 1% in the control group experiencing gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: N/A"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}